This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Wouldn't Touch This Stock With a 10-Foot Pole

This article originally appeared Sept. 9, 2013, on Real Money. To read more content like this, + see inside Jim Cramer's multi-million dollar portfolio for FREE Click Here NOW.

Emeritus (ESC) was the biggest loser on the NYSE Friday, losing 10% for the session. Such declines normally pique my interest, as I like to look for shares that are undeservedly punished. But in the case of Emeritus, I believe the outlook really is bleak.

Based in Seattle, the company operates approximately 500 senior-living facilities. Most of them offer assisted-living arrangements. Some are geared toward skilled nursing care, or toward care for people with Alzheimer's disease or dementia.

The company is headed for its eighth consecutive annual loss, and analysts expect this year's loss -- with estimates at about $2.19 a share -- to be the widest in that eight-year period.

As of June 30, Emeritus had almost $4 billion in long-term debt, and debt was about 19x stockholders' equity. By comparison, that ratio is 1.7x at Kindred Healthcare (KND), which competes with Emeritus in senior-living facilities and also owns hospitals and rehabilitation centers.

On this point, I tend to be conservative: Generally, I will not buy a stock with a ratio higher than 1x.

Valuations at Emeritus are forbidding from a value investor's perspective. There is, of course, no price-to-earnings ratio, since there are no earnings. The stock sells for 5x book value (corporate net worth per share), which is about double the ratio for the average stock and more than double my preferred limit of 2x.

The shares do look more reasonable on a price-to-sales multiple, as they fetch only 0.5x sales. This ratio can often point to a turnaround situation, as new management may be able to come in and reshape the clay of sales into the pottery of earnings.

I do not believe, however, that Emeritus is about to turn around. Care for the elderly is inherently expensive, and it's getting more so with longer life spans and newer medical techniques. The relatives of the elderly often lack enough resources to pay for long-term care, and this will become increasingly true as more baby boomers start to need it.

Private long-term care insurance is spotty, and often not up to the task. That leaves Medicare and Medicaid to carry much of the freight. But both programs, and especially Medicaid, are at risk for budget cuts in this fall's Congressional budget negotiation.

A successful company has a product or service that fills a genuine need, and a customer population that can afford to pay for the product. There is a big need for elder care, all right. But it is difficult and expensive to provide it well, and the ability of the customers to pay for the service is in doubt.

At the time of publication, Dorfman had no positions in the stocks mentioned.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,608.96 -271.40 -1.61%
S&P 500 1,933.08 -36.99 -1.88%
NASDAQ 4,371.1670 -91.7350 -2.06%

Our Tweets

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs